Source: International Congress 2018 – Non-invasive ventilation for acute respiratory failure
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
B. Han (Beijing, China), X. Chen (Beijing, China), L. Gan (Beijing, China), S. Lei (Chongqing, China), Z. Sun (Beijing, China), P. Du (Ningbo, China), L. Sun (Beijing, China), L. Yue (Chongqing, China). Late Breaking Abstract - Severe pneumonia patients may could not benefit from antibiotic combination therapy and non-invasive ventilation(NIV), despite the advanced mode. 2348

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Comparative real world effectiveness of triple therapy versus dual bronchodilation in frequently exacerbating patients with COPD Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018 Late Breaking Abstract - A retrospective analysis of ROX score for predicting treatment failure and progression to invasive ventilation in COVID patients requiring enhanced respiratory support Source: Virtual Congress 2021 – Respiratory failure in COVID19 and beyond Year: 2021 Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial Source: International Congress 2019 – Recent developments in intensive care unit medicine Year: 2019 Late Breaking Abstract - CPAP is effective in treating COVID-19 patients with Type 1 respiratory failure. Source: Virtual Congress 2020 – Nasal high flow and non-invasive ventilation in acute and chronic care Year: 2020 Changes in empirical initial antibiotic therapy in community-acquired pneumonia: assessment of clinical failure versus discordant therapy Source: Eur Respir J 2006; 28: Suppl. 50, 736s Year: 2006 Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial Source: International Congress 2015 – Acute critical care: news from the ICU Year: 2015 Combination therapy of ICSs/LABAs plus montelucastin patients with severe asthma Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD) Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 How often can we use short course therapy in patients with hospital-acquired pneumonia? Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007 Late Breaking Abstract - Adjunctive treatment with oral dexamethasone in adults hospitalised with community-acquired pneumonia: a randomised clinical trial Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020 Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria Source: International Congress 2018 – Notable Studies in Asthma Year: 2018 Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Late Breaking Abstract - Therapeutic drug monitoring in a patient with very advanced XDR-TB Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis Year: 2021 Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning Source: Eur Respir J, 54 (6) 1900824; 10.1183/13993003.00824-2019 Year: 2019 Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim? Source: Breathe, 17 (3) 210056; 10.1183/20734735.0056-2021 Year: 2021 Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy. Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Clinical stability and switch therapy in hospitalised patients with community-acquired pneumonia: are we there yet? Source: Eur Respir J 2013; 41: 5-6 Year: 2013 Late Breaking Abstract - Tiotropium/olodaterol improves pulmonary function in patients with treatment naive COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Combined immunosuppressive therapy including anti-TNFα in a treatment of severe paediatric sarcoidosis – a case report Source: Eur Respir J 2006; 28: Suppl. 50, 829s Year: 2006